U.S. Full Prescribing Information Medication Guide Indication U.S. Healthcare Professionals |En Español
Call
1-888-SOTYKTU
(768-9588)

YOUR CIRCLE OF SUPPORT

SOTYKTU™ 360 SUPPORT logo
SOTYKTU 360 SUPPORT is designed to help people who've been prescribed SOTYKTU get started, with services to support you along your treatment path. SOTYKTU 360 SUPPORT can provide a support team to help guide you, insurance resources to inform you, savings programs that may help you, and continued communications to encourage you.
Ongoing Support Co-Pay Assistance
Your Support Team*
When you begin treatment with SOTYKTU, you aren't facing your journey alone. You'll have a support team available to you along the way. A dedicated SOTYKTU Support Coordinator will be assigned to you. They can help answer your access and affordability questions about SOTYKTU and are available Monday through Friday, 8 AM to
11 PM ET.
We also have additional support team members who can answer questions about SOTYKTU and provide helpful resources.
1-888-SOTYKTU (768-9588) Monday-Friday, 8 AM to 11 PM ET
*While support team members can answer questions about SOTYKTU, they cannot provide medical advice.
Navigating Insurance Benefits†
Your SOTYKTU Support Coordinator will work to help:
  • Explain your insurance coverage and pharmacy benefits
  • Assist eligible commercially insured patients who have been prescribed SOTYKTU to access their medication if it isn't initially covered by insurance. The SOTYKTU Bridge Program,‡ which could be your crossover to coverage, provides up to 3 years of SOTYKTU free of charge while you await a coverage decision from your commercial insurance
  • Provide information about other resources that may be available to you, including the SOTYKTU Co-Pay Assistance Program for eligible commercially insured patients§
†Completion of any reimbursement- or coverage-related paperwork is the responsibility of the healthcare provider and the patient. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.
‡Please see SOTYKTU Bridge Program Terms and Conditions.
INSPIRE OTHERS LIKE YOU
Imagine if, after all the frustration of your moderate to severe plaque psoriasis, you finally see the results you want with SOTYKTU. Wouldn't that be a great story to share with others? Here's your opportunity. Our Share To Inspire program gives people like you a voice and a chance to make a positive difference in another person's life.
Find out how you can participate in this important program and help inspire others to get the results they're looking for. Call us toll-free at 1-855-436-5866 or visit sharetoinspire.com.
David, a person being treated with SOTYKTU™

“Psoriasis made me feel hurt inside and out. I wouldn’t want to shake people’s hands because it just looked so horrible. I felt so self-conscious all the time.”
-David

If, like David, you’ve been living with moderate to severe plaque psoriasis and think your story and experiences may be helpful to others, consider participating in the Share to Inspire program.

David is a real patient on SOTYKTU and was compensated for his time. Your results may vary.

SOTYKTU Co-Pay Assistance Program§
Eligible commercially insured patients may pay as little as $0 a month for SOTYKTU with the SOTYKTU Co-Pay Assistance Card.
SIGN UP FOR CO-PAY
SOTYKTU™ (deucravacitinib) co-pay assistance card
§Please see SOTYKTU Co-Pay additional eligibility requirements and Terms and Conditions.
Financial Assistance
If you're uninsured or underinsured, your SOTYKTU Support Coordinator can help you understand what options may be available to you.
Ongoing Communication and Support
We are not just with you as you begin your treatment journey—we are with you along the way. As part of SOTYKTU 360 SUPPORT, you will receive a Welcome Kit and ongoing support materials that may help you:
  • Be better prepared to start treatment
  • Build a routine and track how you're doing
  • Find encouragement along the way
SOTYKTU™ 360 SUPPORT welcome kit SOTYKTU™ 360 SUPPORT welcome kit
Learn about Pricing Information for SOTYKTU
INTERESTED IN RESOURCES TO HELP GUIDE YOU?
Get more information about SOTYKTU, tips to start your treatment, a My Experience
Tracker to see how you're doing with your goals, and more.
SEE RESOURCES
Important Facts About
SOTYKTU™
(deucravacitinib)
This is a summary of important information that you need to know about SOTYKTU. Your dermatologist can work with you to help answer any questions you may have about this medication. Keep this information in a safe place, so you can refer to it before and during your treatment.
This is a summary of important information that you need to know about SOTYKTU. Your dermatologist can work with you to help answer any questions you may have about this medication. Keep this information in a safe place, so you can refer to it before and during your treatment.
Look out for the following icons as you read:
Talk to your dermatologist
Call a dermatologist right away
Helpful information to remember
What is SOTYKTU?
SOTYKTU is an oral prescription medication that is used to treat:
Moderate-to-severe plaque psoriasis in adults who may benefit from systemic therapy (pills or injections that work inside the body) or phototherapy (treatment using specialized ultraviolet or UV light).
It is not known if SOTYKTU is safe
and effective in children under 18
years of age.
What is the most important information I should know about SOTYKTU?
SOTYKTU may cause serious side effects, including:
Serious allergic reactions. Stop taking SOTYKTU and get emergency medical help right away if you develop
any of the following symptoms of a serious allergic reaction:
  • Feeling faint
  • Swelling of your face, eyelids,
    lips, mouth, tongue, or throat
  • Trouble breathing or
    throat tightness
  • Chest tightness
  • Skin rash, hives
Infections. SOTYKTU is a medicine that affects your immune system. SOTYKTU can lower the ability of your immune system to fight infections and can increase your risk of infections. Your dermatologist should check you for infections before starting SOTYKTU. Some people have had serious infections while taking SOTYKTU, such as infections of the lungs, including pneumonia and tuberculosis (TB) and COVID-19.
Before starting SOTYKTU, your dermatologist should check you for TB. If you have active TB or a history of TB, you may be treated for TB before beginning treatment with SOTYKTU. Your dermatologist should watch you closely for signs and symptoms of TB during treatment with SOTYKTU.
If you get a serious infection, your dermatologist may tell you to stop taking SOTYKTU until your infection is controlled.
Call or see a dermatologist if you notice any symptoms of TB.
Call or see a dermatologist right away if you have an infection or develop any new or worsening symptoms of an infection, including:
  • Fever, sweats, or chills
  • Muscle aches
  • Weight loss
  • Cough
  • Shortness of breath
  • Blood in your phlegm (mucus you cough up)
  • Warm, red, or painful skin or sores on your body different from your psoriasis
  • Diarrhea or stomach pain
  • Burning when you urinate or urinating more often than normal
  • Feeling very tired
SOTYKTU should not be used in people with an active, serious infection, including localized infections. You should not start taking SOTYKTU if you have any kind of infection unless your dermatologist tells you it is okay.
You may be at higher risk of developing shingles (herpes zoster).
Before starting SOTYKTU, tell your dermatologist if you:
  • Have any kind of infection or symptoms of an infection (see symptoms listed in “What is the most important information I should know about SOTYKTU?”), as SOTYKTU may lower the ability of your immune system to fight infections and may increase your risk of infections. Infections include:
    • Any infection for which you are currently being treated.
    • Any infection that will not go away or a history of infections that keep coming back.
    • Tuberculosis (TB), a type of lung infection. Tell your dermatologist if you have TB or have been in close contact with someone with TB.
    • Hepatitis B or C. Tell your dermatologist if you have or have had hepatitis B or C.
After you start taking SOTYKTU, call your dermatologist right away if you have an infection or symptoms of an infection. SOTYKTU can make you more likely to get infections or make any infections you have worse.
Cancer. Certain kinds of cancer including lymphoma have been reported in people taking SOTYKTU. Tell your dermatologist if you have ever had any type of cancer.
Muscle problems (rhabdomyolysis). SOTYKTU can cause muscle problems that can be severe. Treatment with SOTYKTU may increase the level of an enzyme in your blood called creatine phosphokinase (CPK) and can be a sign of muscle damage. Increased CPK is common in people taking SOTYKTU. Your dermatologist may tell you to stop taking SOTYKTU if the amount of CPK in your blood gets too high or if you have signs and symptoms of severe muscle problems. Tell your dermatologist right away if you have any of these signs or symptoms of severe muscle problems:
  • Unexplained muscle pain, tenderness, or weakness
  • Feeling very tired
  • Fever
  • Dark-colored urine
A serious side effect is a side effect that may require medical treatment or hospitalization, cause permanent damage, or be life-threatening or sometimes even fatal.
What should I discuss with my dermatologist before starting treatment?
Talk to your dermatologist about all of your medical conditions, including if:
  • You have liver or kidney problems.
  • You have high levels of fat in your blood (triglycerides).
Talk to your dermatologist if you have recently received or are scheduled to receive a vaccine (immunization).
During treatment with SOTYKTU, you should avoid receiving live vaccines (vaccines that use a small
amount of the weakened virus). Common live vaccines (among others) include:
  • Measles, mumps, and rubella (MMR)
  • Rotavirus
  • Smallpox
  • Chickenpox
  • Yellow fever
Talk to your dermatologist if:
You are pregnant or plan to become pregnant. It is not known if SOTYKTU can
harm your unborn baby.
You are breastfeeding or plan to breastfeed. It is not known if SOTYKTU passes
into your breast milk.
Tell your dermatologist if you become pregnant or think you are pregnant during treatment
with SOTYKTU. Report pregnancies to Bristol-Myers Squibb by calling 1-800-721-5072.
Talk to your dermatologist about all of the medications you are taking, including:
  • Prescription medicines
  • Over-the-counter medicines
  • Vitamins
  • Herbal supplements
Keep a list of them to show your dermatologist and pharmacist when you get a new medicine.
What are the possible side effects of SOTYKTU?
SOTYKTU may cause serious side effects, including:
  • Changes in certain laboratory test results. Changes in laboratory tests have happened in some people taking SOTYKTU. Your dermatologist may do blood tests before you start taking SOTYKTU and during treatment with SOTYKTU to check for the following:
    • Increased triglycerides. Too much fat in your blood can cause problems with your heart.
    • Increased liver enzymes. If your liver enzymes increase too much, your dermatologist may need to do additional tests on your liver and may tell you to stop taking SOTYKTU if they think that SOTYKTU is harming your liver.
  • Potential risks from Janus kinase (JAK) inhibition. SOTYKTU is a tyrosine kinase 2 (TYK2) inhibitor. TYK2 is in the JAK family. It is not known whether taking SOTYKTU has the same risks as taking JAK inhibitors. Increased risk of death (all causes) has happened in people who were 50 years of age and older with at least 1 heart disease (cardiovascular) risk factor who were taking a JAK inhibitor used to treat rheumatoid arthritis (RA) compared to people taking another medicine in a class of medicines called TNF blockers. SOTYKTU is not for use in people with RA.
What are the most common side effects of SOTYKTU?
The most common side effects of SOTYKTU include:
  • Common cold, sore throat, and sinus infection (upper respiratory infections)
  • Cold sores (herpes simplex)
  • Sores on the inner lips, gums, tongue, or roof of the mouth (canker sores)
  • Inflamed hair pores (folliculitis)
  • Acne
These are not all of the possible side effects of SOTYKTU.
Talk to your dermatologist, pharmacist, or other members of your healthcare team for more information about side effects. If you experience any side effects and would like to report them to the FDA, you can visit www.fda.gov/medwatch or call 1-800-FDA-1088.
How should I take SOTYKTU?
Take SOTYKTU exactly as your
dermatologist tells you.
Take 1 time every day
Can be taken with or without food
Do not crush, cut, or chew the SOTYKTU tablets
SOTYKTU is available as a 6 milligram (mg) pink, round pill.
Each pill is marked with “BMS 895” and “6 mg.”
Do not take SOTYKTU if you are allergic to deucravacitinib or any of the ingredients in SOTYKTU.
Inactive ingredients: anhydrous lactose, croscarmellose sodium, hypromellose acetate succinate, magnesium stearate, microcrystalline cellulose, and silicon dioxide
Pill coating inactive ingredients: polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, iron oxide red and yellow
How should I store SOTYKTU?
Store SOTYKTU at room temperature between 68°F to 77°F (20°C to 25°C).
Keep SOTYKTU and all medicines out of reach of children.
For more information, please see the U.S. Full Prescribing Information and Medication Guide for SOTYKTU.
Talk to your healthcare team for more information about this medication.
1787-US-2300695 12/231787-US-2200851 02/23
1787-US-2200571 09/22
SOTYKTU and SOTYKTU logo are trademarks of
Bristol-Myers Squibb Company.
All other trademarks are property of their respective owners.
© 2023 Bristol-Myers Squibb Company.
1787-US-2200141 09/22
Legal Notice|Privacy Policy|
Your Privacy Choices |Site Map
This website is intended for U.S. residents
18 years of age or older.
SOTYKTU, SOTYKTU 360 SUPPORT, and SOTYKTU logo are trademarks of Bristol-Myers Squibb Company.
All other trademarks are property of their respective owners.
© 2023 Bristol-Myers Squibb Company.
1787-US-2200141 09/22
Legal Notice|Privacy Policy|
Your Privacy Choices |Site Map
This website is intended for U.S. residents
18 years of age or older.

This website is best viewed
using the horizontal display
on your tablet device.

This website is best viewed
using the vertical display
on your mobile device.